Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01165554 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 203
- Enrollment target
NCT01165554 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 203 participants.
The verdict
NCT01165554, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 203 participants
- Enrollment target
Study Summary
To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
Interventions
- DRUG [18F] Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01165554
The ClinicalTrials.gov registry entry for NCT01165554 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F] Flutemetamol is the first listed.
NCT01165554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01165554 about?
NCT01165554 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels". To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
What is the current status of trial NCT01165554?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 203 participants. The study started on 2010-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01165554?
The interventions under investigation include: [18F] Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01165554?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.